Latest Conneqt Health (ASX:CQT) News

CONNEQT Health has raised $3.1 million through an institutional placement to fuel growth of its Pulse vascular health device, supported by both new and existing investors including its largest shareholder.

CONNEQT Health’s Pulse arterial health monitor sales have outpaced expectations with over 200% growth in the December quarter, driven by efficient marketing and early subscription uptake.

CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.

CONNEQT Health reported a $2.6 million operating cash outflow in the September quarter but secured $2 million through a convertible note, while expecting a $1.6 million R&D tax refund to shore up liquidity.

CONNEQT Health has landed a significant Phase 2b clinical trial contract in the US, advancing its footprint in cardiovascular disease research with proprietary vascular assessment technology.

CONNEQT Health reports robust sales momentum for its CONNEQT Pulse arterial health monitor, with quarterly sales growth exceeding 50% and a fresh order for 10,000 units to meet rising demand.

CONNEQT Health has disclosed significant revisions to its 2025 financial results, highlighting increased losses driven by a larger-than-expected fair value write-down on its inHealth investment and a heightened inventory provision.

CONNEQT Health has raised $2 million through a convertible note facility with a director-owned entity, providing fresh capital to support its growth plans. Shareholder approval will be key to unlocking the full benefits of this funding.